^
Association details:
| Biomarker: | KRAS wild-type |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Vectibix (panitumumab) (EGFR inhibitor) + Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer
Published date:
01/19/2021
Excerpt:
Approximately half of all patients with metastatic colorectal cancer (mCRC) have KRAS and NRAS (RAS) wild-type tumor…The combination of cabozantinib and panitumumab had signals of clinical activity. A lower starting dose of cabozantinib may offer comparable clinical activity and improved long-term tolerability.
DOI:
https://doi.org/10.1002/onco.13678
Trial ID:
